A Phase II Trial of GnRH Agonist for the Preservation of Ovarian Function After Hematopoietic Cell Transplantation (HCT).
Phase of Trial: Phase II
Latest Information Update: 19 Jul 2017
At a glance
- Drugs Leuprorelin (Primary) ; Leuprorelin (Primary)
- Indications Ovarian disorders
- Focus Therapeutic Use
- 19 Jun 2017 Status changed from active, no longer recruiting to discontinued.
- 23 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 23 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.